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Analysis of insulin.like growth factors (IGF)-I, and .11, type II IGF
receptor and IGF-binding protein-2 mRNA and peptide levels in normal
and nephrectomized rat kidney. Immunocytochemistry, in situ hybridiza-
tion, and radioimmunoassay were employed to examine the cellular
distribution of mRNAs and proteins for IGF-I, II, IGF-II/M6P receptor,
IGFBP2 as well as the levels of IGF-I and II in normal and unilaterally
nephrectomized (Nx) adult rat kidneys. A similar distribution of immu-
noreactive IGF-I, and -II as well as IGF-II/M6P receptor was found in the
principal cells of the cortical collecting duct and in all cells of the inner
medullaty collecting duct. In addition, immunostainable IGF-I and IGF-
II/M6P receptor were noted in some inner medullary loops of Henle, while
IGFBP2 was seen in the collecting ducts and ioops of Henle of the inner
medulla and the renal vasculature of all animals. By comparison, in Situ
hybridization revealed IGF-I mRNA only in the medullary thick ascending
limbs while IGF-II mRNA was localized to the wall of the renal
niicrovasculature in all kidneys. IGFBP2 mRNA was localized to the renal
corpuscle and to inner medullary interstitial cells of all kidneys. These data
suggest that renal IGF-I and IGFBP2 are synthesized at upstream sites
along the nephron and then transported downstream for interaction with
IGF receptors. Following nephrectomy, the renal levels of IGF-I peptide
and mRNA were elevated at both 5 and 33 days post-nephrectomy,
supporting a potential functional role for IGF-I in stimulating the
structural and functional recovery in compensatory hypertrophy.
The insulin-like growth factor (IGF) system consists of two
polypeptides, two structurally non-related receptors (IGFR-I and
IGF-II/M6P) and six high-affinity binding proteins (IGFBPs) [1,
21. In the mammalian system, IGFs demonstrate anabolic [3],
insulin-like [1 and mitogenic activities [5, 61; induce differentia-
tion of fetal tissues [7]; regulate tissue growth [8, 9]; participate in
tissue regeneration [10—12]; and promote differentiated cellular
functions [13—15]. In kidney, IGFs can alter proximal tubular
transport processes [16—21], stimulate vectorial Na transport in
toad urinary bladder [22, 23] and control glomerular filtration rate
and renal plasma flow levels [24—28]. Although in vitro evidence
supports their functional role in kidney growth, the site of IGFs'
synthesis and action in vivo is currently unclear.
The kidney is a target of circulating [9, 16—21, 24—28, 38—40]
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and locally produced [11, 29—38] IGF-I and II, since both types of
IGF receptors are localized on kidney cells [36—39]. The ligand-
mediated receptor activation is subject to regulation by at least
four binding proteins: IGFBP1, 2, 3, and 5 [35, 36, 38, 39, 41]. In
the adult kidney, IGF-I predominates and can influence renal
function/morphology in normal [16—21, 24—28] and disease con-
ditions, such as compensatory hypertrophy, hypersomatotropism,
and diabetes mellitus [8, 10, 11, 25, 26, 42—51], and participate in
tissue regeneration/recovery of tubular function following acute
[52—54] and chronic [55] injury. During kidney development,
IGF-II predominates and is localized to the glomerular progenitor
cells of the S-shaped body and in the medullary interstitium near
forming vasa recta along with IGFBP2 and both types of IGF
receptors [38, 56]. Interestingly, the development of cultured rat
metanephri can be blocked with anti-IGF-I, anti-IGF-II and anti-
IGF-II receptor antibodies, suggesting a role for IGF-II in normal
nephrogenesis [57].
The cellular sites of renal IGFs' (IGF-I and II, types I and
H/M6P IGF receptors, and IGF binding proteins 1 and 2) synthesis
and action were initially studied using standard immunocytochem-
ical techniques and more recently by in situ hybridization proto-
cols (Table 1) [33, 36, 37, 42, 44, 53, 58—61}. When the first IGF-I
immunocytochemical studies were performed, it was generally
assumed that those cells showing IGF-I immunoreactivity repre-
sented the cellular site for IGF-I synthesis which lead to conclu-
sions about the renal IGF system. It is now known that a cellular
site showing IGF immunoreactivity does not conclusively prove
that the protein being investigated was synthesized in that cell but
may represent sites for receptor binding. On the other hand, in
situ hybridization does pinpoint cellular sites of IGF gene tran-
scription. Because these two techniques have the potential of
yielding different information, the current literature on the renal
IGF system possesses discrepancies as to where some these
proteins are synthezed versus bound to a receptor. In order to
determine the levels, cellular sites of gene expression and cellular
distribution of IGF components, a set of studies combining
immunocytochemistry and in situ hybridization, and radioimmu-
noassay are required. In the current investigation, we performed
in situ hybridization and immunocytochemistry on serial kidney
tissue sections to analyze the cellular localization of mRNA and
protein of IGF system components, the first IGF study in the
literature to have such an experimental design. To determine
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Table 1. Patterns of gene expression and immunocytochemical
localization of components of the IGF system in the adult rat kidney
Component Immunocytochemistry mRNA
IGF-I Glomerulus [531
THL [42, 53, 58, 59,a]
mTAL [59]
DCT [591
CCD [33, 44, 53, 59]
IMCD [33, 42, 44, 53, 58, 59]
Glomerulus [33, 37, 53]
PT [33, 37, 531
THL [37, 53]
mTAL [36,a]
CCD [37, 53]
IMCD [33, 37, 53]
IGF II CCD'
IMCD
Microvessels []
Not found [36]
IGFR-I J Glomerulus [36]
.j. PT [361
mTAL [36]
DCT [36]
CD [36]
. Interstitium [36]
IGFR-II Glomerulus [60, 61]
PT [59]
THL []
CCD ri
IMCD []
. mTAL [36]
. DCT [36]
CCD [36]
MCD [36]
IGFBP1 IHL [59]
mTAL [59]
. DCT [591
CCD [59]
MCD [59]
mTAL [36]
IGFBP2 THL []
MCD [i']
Renal artery []
Glomerulus [36,']
Interstitial cell [36,a]
Renal artery [k']
Transitional epithelium []
a Data collected from the present study by Evan et al
Abbreviations are: . , low level of expression; PT, proximal tubules;
THL, thin loops of Henle; mTAL, medullary thick ascending loops of
Henle; DCT, distal convoluted tubules; CCD, cortical collecting ducts;
MCD, entire medullary collecting duct; IMCD, inner medullary collecting
duct; CD, entire (cortical and medullaiy) collecting duct.
whether the IGF system plays a role in renal hypertrophy, the
same approach was combined with radioimmunoassay to analyze
the cellular localization of mRNA and protein of IGF-I, and II in
normal and unilaterally nephrectomized adult rat kidneys.
Methods
Experimental animals and tissue preparation
Male Sprague-Dawley rats (8 weeks old, Zivic Miller) under-
went either unilateral nephrectomy (Nx) or sham operation.
Animals from each group (sham or Nx) were allowed to recover
from anesthesia and given food and water ad libitum. At either 5
or 28/33 days post-surgery, the animal's body wt was determined
prior to sacrifice. Animals from each group were used for either
serum/tissue IGF measurement or for immunocytochemical/in
situ hybridization studies. Serum and renal tissue IGF-I and II
levels were measured in sham and Nx animals at 5 (N = 5) and 33(N = 4) days post-surgery. All animals were decapitated, a serum
Table 2. Serum IGF concentrations
IGF-I ng/g tissue IGF-II ng/g tissue
Group Day 5 Day 33 Day 5 Day 33
Sham 308.7 44.0 298.7 17.4 45.6 3.5 49.2 3.9
N 5 4 5 4
Nx 446.7 57.6 346.2 8.1 85.5 11.6 50.9 4.5
N 5 4 5 4
Data are mean SCM.
Table 3. Serum IGF concentrations
IGF-l nglml IGF-IT nglml
Group Day 5 Day 33 Day 5 Day 33
Sham 339.8 14.5 415.7 20.6 20.2 3.2 25.2 3.3
N 5 3 5 3
Nx 342.4 24.1 402.3 16.9 18.1 1.6 23.7 3.5
N 5 4 5 4
Data are mean SEM.
sample collected and the kidneys quickly removed, weighed and
then quick frozen in liquid nitrogen for future measurement of
IGF-I and IGF-II levels as previously described [62, 63].
Immunocytochemistry studies were performed on sham and Nx
animals (four animals per group) at five days post-surgery. All
animals were anesthetized with sodium pentobarbital (0.10 g/kg,
i.p.) and the kidneys were perfused through the aorta with 100 ml
of 0.02 M PBS (pH 7.4) at a pressure of 150 mm Hg followed by
300 ml of 4% paraformaldehyde in PBS. The kidneys were
post-fixed overnight in 4% paraformaldehyde in PBS, embedded
in paraffin, sectioned in 6 mm thickness and mounted on pre-
coated poly-L-lysine slides (Stat Path, Riverwood, MD, USA).
In situ hybridization studies were performed on sham (N = 5
per group) and Nx (N = 5 per group) animals at 5 and 28 days
post-surgery. All animals were anesthetized with sodium pento-
barbital (0.10 g/kg i.p.), the abdominal cavity opened and the
kidneys quickly removed. Each kidney was placed in a container
of powdered dry ice for quick freezing. Thereafter, serial sections
were cut from the mid-plane of each kidney at 16 microns and
mounted on glass slides pre-coated with poly-L-lysine. The sec-
tions were then fixed with 4% formaldehyde in I X PBS (10 mm),
passed through 0.1 M triethanolamine hydrochloride in 0.25%
acetic anhydride (10 mm), washed with 2 X SSC and then
dehydrated by graded ethanols.
Immunocytochemistiy
Staining was accomplished using an avidin-biotin immunoper-
oxidase technique [64]. All reagents used were purchased from
Vector Laboratories, Inc. (Burlingame, CA, USA). Monoclonal
antibody against IGF-II was purchased from Amano Pharmaceu-
tical Co. (Nagoya, Japan). Anti-IGF-I rabbit antiserum was kindly
provided through the National Institute of Diabetes, Digestive
Fig. 1. Immunohistochemical localization of insulin-like growth factor II (IGF-II) in normal adult rat kidneys. A. Intense immunoreactivity for IGF-H in
the principal cells (arrows) of the cortical straight collecting ducts (CCD) and (B) in all cells of the inner medullary collecting ducts (JMCD). A & B
>(350. Publication of this figure in color is made possible by funding from Eli Lilly and Company.
Fig. 2. Immunohistochemical localization of IGF-I in normal adult rat kidneys. Immunostainable IGF-I was seen in the principal cells (arrows) of the
cortical straight collecting ducts (CCD) (A), all cells of the inner medullary collecting ducts (IMCD) and (B) some inner medullary loops of Henle (LH).
A & B x350. Publication of this figure in color is made possible by funding from Eli Lilly and Company.
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Fig. 3. Immunohistochemical localization of IGF-I and -II in the kidneys of unilaterally Nx animals. Identical localization and intensity of IGF-I (A, cortex;
B, inner medulla) and IGF-II (C, cortex; D, inner medulla) staining was seen in the kidney of the Nx animals compared to sham controls (Fig. I A, C;
Fig. 2 A, B). CCD, cortical collecting duct; IMCD, inner medullary collecting duct; arrow, principal cells. A-D X350. Publication of this figure in color
is made possible by funding from Eli Lilly and Company.
and Kidney Diseases (NIDDK) and the National Hormone and
Pituitary Program (NFIPP) by Drs. L. Underwood and J.J. Van
Wyk, (University of North Carolina, Chapel Hill, NC, USA).
Anti-IGF-II/M6P receptor rabbit serum was provided by Dr.
Peter Nissley of the National Cancer Institute. Anti-IGFBP2
rabbit antiserum against bovine IGFBP2 was kindly provided by
Dr. David Clemmons, University of North Carolina.
Kidney sections for the nephrectomized and sham animals were
paired and stained at the same time. After deparaffinization and
rehydration, kidney sections were blocked sequentially with 0.6%
hydrogen peroxide in 80% methanol, an avidin-biotin blocking
solution (Vector Laboratories) and 2% normal horse serum. The
sections were then incubated with the primary antibody at 1:25
dilution at 4°C for 16 hours. Antibody dilutions used were as
follows: IGF-I 1:150; IGF-II 1:25; IGF-II/M6P receptor 1:100;
and IGFBP2 1:500. Thereafter, a biotinylated horse anti-mouse
secondary antibody (for the monoclonal antibody against IOF-Il)
or a biotinylated goat anti-rabbit secondary antibody was applied
to the sections and incubated for 30 minutes. Next, the sections
were incubated for 45 minutes with a preformed avidin and bio-
tinylated horseradish peroxidase complex. The antigen-antibody
complex was visualized by incubation with an aminoethyl carbozol
peroxidase substrate solution for 20 minutes. The tissue sections
were counterstained with Mayer's hematoxylin and coverslipped.
Specificity of immunostaining
The specificity of the immunostaining for IGF-II was demon-
strated by the following approaches. For IGF-II immunostaining,
adjacent sections were incubated with a like dilution of either
non-immune mouse serum (Dako Corporation, Carpinteria, CA,
USA) or the non-retained elute after applying IGF-II monoclonal
antibody to an IGF-II affinity column. The non-retained protein
peak collected from the IGF-II affinity column was pooled and
concentrated to its original volume for use as the immunoab-
sorbed control. Specificity for immunostaining of IGF-I, IGF-II/
M6P receptor and IGFBP2 was demonstrated by incubating
adjacent sections with the antibody or a like dilution of non-
immune mouse serum (Dako Corporation, Carpinteria, CA,
USA).
In situ hybridization
The rat IGF-I, II and IGFBP2 cDNA clones used to probe
synthesis have been previously described [36]. Protocols for
35S-labeled cRNA probes labeling pre- and posthybridization
treatment were described in detail previously [65]. Briefly, the
hybridization solution was prepared by adding the 35S-labled
cRNA probes (1 X 106 DPM/100 i1 hybridization solution) to the
hybridization buffer composed of 50% formamide, 50 mvt TRIS,
2.5 mM EDTA, 0.2 M NaCl, 10% dextran sulfate, 1 X Denhardt's
solution, 250 mg/mi tRNA and 50 mrvi dithiothreitol. After the
hybridization solution was added to the sections, the slides were
covered by glass coverslips and placed in a humidified chamber for
overnight (15 hr) incubation at 55°C. Following incubation the
slides were washed several times in 4 X SSC to remove the
coverslips and hybridization solution. The slides were then dehy-
drated through a graded series of ethanols, immersed in 50%
formamide (10 mm, 60°C), RNase-A (20 g/ml, 30 mm), 0.1 X
SSC (15 mm, 50°C), again dehydrated in a graded series of
ethanols and air dried. The sections were apposed to Hyperfilm-
beta Max (Amersham) for one to six days and the film was then
processed with GBX developer and fixer (Eastman Kodak, Roch-
ester, NY, USA). Sections were stained with H & E.
Each cRNA probe produced a specific and different pattern of
hybridization in the adult kidney. The level of nonspecific signal,
as determined by hybridization of parallel tissue sections with a
'sense' probe synthesized from the IGFR-I clone, was minimal.
RNase treatment of tissue sections prior to hybridization resulted
in no hybridization signals.
Images of the kidney were captured off from the Hyperfilm
using a video camera (Dage-MTI, Inc.) with the assistance of an
Image-i (Universal Imaging Corp.) program. For each probe
studied, a selected region of the kidney was captured from three
different sections for each animal. Images from all sections of a
given experiment were captured and electronically stored in one
session to ensure uniform transmittance conditions. Results were
quantitated using NIH Image (National Institutes of Health).
Three optical density readings were taken of each area of interest
from each captured image and the value expressed as "arbitrary
optical density" (AOD). Statistical analysis was done using a
repeated measures ANOVA. A P < 0.05 was considered as an
indication of a significant difference between means.
Measurement of IGF-I and IGF-II levels
After the kidneys were removed, they were weighed at 4°C and
cut longitudinally. Thereafter, both IGF-I and IGF-II were ex-
tracted from the serum samples by the modified formic acid!
acetone methods of Bowsher et al [62] and the renal tissue
peptide levels were measured by nonequilibrium RIAs using rat
IGF-II as the standard [63].
Results
Kidney IGF levels
At both 5 and 33 days after Nx, the level of IGF-I was
significantly higher than that of IGF-II (Table 2) at both time
points. Five days following Nx, the renal levels of both IGF-I and
-II were elevated compared to levels in the sham animals (P <
0.001; Table 2). Thirty-three days post-Nx, the IGF-I level re-
mained elevated, although it was lower than at five days post-Nx
(Table 2). However, the IGF-II level was not significantly different
from the shams at this time point (Table 2). No differences were
noted in serum IGF-I or -II levels between control and Nx animals
at either 5 or 33 days post-nephrectomy (Table 3). At 5 and 33
days post-surgery, body wt was not significantly different in control
(333.6 14.3 g and 437.0 24.5 g) and nephrectomized animals
(330.6 14.3 g and 445.8 12.6 g). However, at both 5 and 33
days post-surgery, kidney weights were significantly increased in
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Fig. 4. Immunohistochemical localization of IGF-II/M6P receptor in the kidney of sham and Nx animals. In the sham animals, immunostainable
IGF-II/M6P receptor was seen in (A) the principal cells (arrows) of the initial and cortical straight collecting duct, and (B) all cells of the inner medullary
collecting ducts and majority of inner medullary loops of Henle (LH). Identical localization and intensity of IGF-II/M6P receptor was seen in the kidney
(B, D) of Nx animals when compared to the sham (C). A-D x350. Publication of this figure in color is made possible by funding from Eli Lilly and
Company.
Fig. 5. Immunohistochemical localization of JGFBP2. In the sham animals, immunostainable IGFBP2 is seen in the cells of the collecting ducts (IMCD)
and loops of Henle (LH) of the inner medulla (A) and in the tunica media of renal and interlobar arteries (arrows) (B). A & B X350. Publication of
this figure in color is made possible by funding from Eli Lilly and Company.
the nephrectomized (1.6 0.2 g and 2.1 0.1 g) compared to
control animals (1.2 0.1 g and 1.5 0.2 g).
Immunocytochemistiy
IGF-I and -II in normal and the remaining kidney following
nephrectomy. On serial kidney sections, we found IGF-I and -II
immunostaining co-localized in the principal cells of the cortical
collecting duct and all cells of the inner medullary collecting ducts,
with additional IGF-I immunostaining in some inner medullary
loops of Henle. In particular, specific IGF-II immunostaining was
localized to the collecting duct system in the cortex and medulla,
especially in the initial (connecting segment) and cortical straight
collecting ducts of the cortex (Fig. 1A) and in the inner medullary
collecting ducts (Fig. IB). There, immunoreactive IGF-II was
found only in the principal cells (not the intercalated cells) of the
initial collecting ducts and the cortical collecting duct, while all
cells of the inner medullary collecting duct were positive. Inter-
calated cells of the cortical collecting ducts were easily identified
in serial sections stained with H & E (Fig. 1A). Cells of the outer
medullary collecting duct showed weak or no immunostaining for
IGF-II. When non-immune serum and immunoabsorbed control
substituted for the primary antibody, no immunostaining was seen
(not shown). Specific IGF-I immunostaining was found in the
collecting duct system of the cortex and medulla as well as some
loops of Henle in the inner medulla. In particular, the immuno-
histochemical localization of IGF-I was noted in the principal cells
of the initial and cortical straight collecting duct cells (Fig. 2A), all
cells of the inner medullary collecting ducts (Fig. 2B), and in some
inner medullary loops of Henle (Fig. 2B). Compared to sham
operated rats (Fig. 2 A, B), identical cellular localization of IGF-I
(Figs. 3 A, B) and IGF-II (Fig. 3 C, D) was found in kidneys from
rats which underwent unilateral nephrectomy.
Type II/M6P IGF receptor in sham and nephrectomized animals.
Specific IGF-II/M6P receptor immunostaining was localized in
the principal cells of the initial and cortical straight collecting
ducts (Fig. 4A), all cells of the inner medullary collecting ducts
(Fig. 4B), and a majority of the loops of Henle of the inner
medulla (Fig. 4B). An identical cellular localization pattern for
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Table 4. AOD measurements of IGF-I
Group Days Cortex
Outer
medulla
Inner
medulla
Sham 5 0.11 0.02a 0.87 0.19 0.09 0.01
N = 15 28 0.10 0.02 0.47 0.13 0.09 0.01
Nx 5 0.08 0.02 0.96 0.21 0.08 0.02
N = 15 28 0.10 0.01k' 0.65 0.24c 0.10 0.01
a Mean su
b P < 0.001, increased IGF-I level at 28 days compared to 5 day value
P < 0.00 1, increased IGF-I level in Nx group at 28 days compared to
sham level at 28 days
for the sham or nephrectomized animals using non-immune rabbit
serum (not shown).
In situ hybridization
Fig. 6. IGF-I gene expression in the kidney of normal adult rat. A. The
IGF-I mRNA is localized the inner stripe of the outer medulla (ISIOM).
At higher magnification (B), IGF-I mRNA is seen concentrated in the
epithelial cells of the thick ascending limbs (mTAL) of the loop of Henle.
A x7; B X750.
IGF-II receptor was noted in the remaining kidney of the
unilateral nephrectomized animals (Fig. 4 C, D). No immunos-
taming was noted in kidney sections from sham and nephrecto-
mized animals when non-immune mouse serum was applied (not
shown).
Binding protein (IGFBP2) in sham and nephrectomized rats.
Specific IGFBP2 immunostaining was noted only in the collecting
ducts and loops of Henle in the inner medulla and in the tunica
media of the renal artery and interlobar arteries (Fig. 5 A, B). No
staining of the nephrons or vasculature was seen in the cortex (not
shown). An identical cellular localization pattern for IGFBP2 was
noted in the remaining kidney of the unilateral nephrectomized
animals (not shown). No staining was noted in the control tissues
IGF-I mRNA was localized to cells of the thick ascending limb
of the loop of Henle (mTAL) in the outer medulla of control and
Nx kidneys (Fig. 6 A, B). From 5 to 28 days post-Nx, IGF-I mRNA
levels (Table 4) increased in the cortex and inner medulla of the
Nx kidney (P < 0.001), while these same areas in the sham
animals either remained unchanged (inner medulla) or decreased
(cortex) (P < 0.001). IGF-I mRNA levels were elevated in the
outer medulla of the 28-day-old post-Nx animal compared to the
age matched control (P < 0.001). By comparison, IGF-II mRNA
was localized to the wall (possibly the vascular smooth muscle
cells) of the renal microvasculature from the intralobar arteries to
the arterioles (Fig. 7 A, B, C). No quantitative differences in the
IGF-II mRNA levels were detected between the control and Nx
kidneys over time (Table 5).
IGFBP2 mRNA was localized to the renal glomerulus (Fig. 8 A,
B), the interstitial cells of the inner stripe and papillary tip (Fig.
8C), the renal artery, and transitional epithelium of the renal
calyx. IGFBP2 mRNA levels (Table 6) showed significant differ-
ences (P < 0.001) between different locations but not between
treatment groups. The distribution pattern of IGFBP2 from
highest to lowest was glomerulus > inner stripe > cortex> inner
medulla = outer stripe. The glomerular IGFBP2 levels increased
over time for the Nx kidneys (P < 0.001), while all other locations
showed a decrease for both control and Nx kidneys (P < 0.001).
Discussion
This is the first investigation of renal IUF system gene expres-
sion in normal and nephrectomized rats employing immunocyto-
chemistry, in situ hybridization and radioimmunoassay concur-
rently. In normal adult rat kidneys, the cellular distribution of
immunoreactive IGF-I and II, and IGFBP2 differs from that of
their mRNAs (Table 1). In particular, immunoreactive IGF-I and
II were both predominately localized to cells in the cortical and
inner medullary collecting tubules, whereas immunoreactive IG-
FBP2 was localized to cells of inner medullary collecting tubules
and loops of Henle and proximal segments of the renal vascula-
ture. By comparison, IGF-I mRNA was localized to the cells of
the thick ascending limbs of the loops of Henle, IGF-II mRNA
was localized to the walls of renal microvessels (intralobar arteries
to afferent arterioles), and IGFBP2 mRNA was localized to
glomeruli and inner medullary interstitial cells. Therefore, immu-
noreactive IGF-I and II and IGFBP2 are present in cells down-
stream to the sites of their synthesis in a nephron.
4,
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Fig. 7. IGF-II gene expression in the kidney of normal adult rat. A. Low
magnifications, IGF-II mRNA localization in the normal adult kidney is
difficult to detect. At higher magnifications, IGF-II mRNA is seen
localized to the vascular wall (arrows) of the renal microvasculature (B is
an arcuate artery and C is an interlobar artery). A x7; B-C X950
Table 5. AOD measurements of IGF-II
Group Days Tissue Vessel
Sham 5 0.37 0.07a 0.80 0.l7
N = 15 28 0.39 0.07 0.79 0•18h
Nx 5 0.30 0.09 0.84 019b
N = 15 28 0.40 0.08 0.83 018h
a Mean SD
b P < 0.00 1, higher IGF-II levels in vessel wall compared to nearby
tissue
Discrepancies of cellular localization of IGF-I mRNA and
immunoreactive IGF-I were previously reported [33, 36, 37, 42,
44, 53, 58—61]. Such discrepancies should not be surprising, since
immunocytochemistry and in situ hybridization detect different
gene products. Immunocytochemistry detects the presence of a
cellular protein which may be synthesized in the same cell or in
other cells from where the protein is released into the extracellu-
lar space. Because of the relatively low sensitivity, a cell synthe-
sizing the peptide may not be immunostained positive if the
peptide is immediately released upon synthesis (like both IGFs).
On the other hand, a cell can be immunostained positive if
extracellular peptide can bind to cell surface receptors and then
be internalized. Therefore, immunocytochemistry identifies the
sites of protein synthesis and/or receptor binding which results in
either signal transduction or degradation [66]. On the other hand,
in situ hybridization detects a gene transcript (mRNA) which may
or may not be translated into a protein, and thereby identifies the
cells which have the potential to produce a particular peptide.
Hammerman and Miller [67] have suggested that the rat kidney
has multiple sites (basically the entire nephron) for IGF-I pro-
duction, based on mRNA analysis by different techniques using
tissue homogenates or fragments (Table 1). Such an approach is
likely to produce an erroneous result, unless the homogeneity of
the preparation is proven. Using a digoxigenin labeled probe and
in situ hybridization, Matejka et al [37] localized IGF-I mRNA
primarily to the distal nephron (thin loops of Henle to medullary
collecting ducts), which is similar to the localization of immuno-
reactive IGF-I (Table 1). This result needs to be reproduced with
a radioactive probe, since the digoxigenin protocol, like other
non-isotopic labeling methods, is insensitive, nonquantitative, and
often presents inconsistent mRNA distribution [66, 68]. Chin,
Zhou and Bondy [36] have previously identified the medullary
thick ascending limbs (mTAL) as the predominant sites of IGF-I
gene expression in the adult rat kidney, a cellular pattern repro-
duced in the current study. Both studies localized IGF-I mRNA
with in situ hybridization using an 35S-labeled specific cRNA
probe, and therefore provided convincing evidence that the cells
of the medullary thick ascending limbs are the predominant sites
for IGF-I production.
In distal nephrons, immunoreactive IGF-I and -II were found in
a similar distribution as that of IGFR-I [36] and IGF-II/M6P
mRNA, suggesting that IGFs' binding and/or internalization
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Fig. 8. IGFBP2 gene expression in the kidney of normal adult rat. A.
IGFBP2 mRNA localized to glomeruli (arrows) through out the renal
cortex. At higher magnifications, IGFBP2 mRNA is seen localized to the
tuft (arrow) and parietal cells of the renal glomerulus (B) and to
interstitial cells (IC) (C) of the inner medulla. A x7; B X600; C X750.
Table 6. AOD measurements of IGF-BP2
Outer Inner Inner
Days Cortex Glomerulus strips stripe medulla
5 0.07 0.Ola 0.48 0.10 0.06 0.01 0.15 0.05 0.06 0.01
28 0.06 0.01 0.47 0.10 0.05 0.01 0.10 0.02 0.05 0.01
5 0.07 0.01 0.43 0.11 0.06 0.01 0.16 0.09 0.07 0.01
28 0.07 0.01 0.49 010b 0.06 0.01 0.14 0.04 0.05 0.01
a mean SD
b P < 0.001, increased BP-2 level in Nx group at 28 days compared to 5
day Nx level
occurs predominately in this nephron segment. Since the site of
IGF-I's synthesis is upstream and almost all biological action of
IGFs are mediated by IGFR-I, the distal nephron is likely to be
the site of renal IGF-I's action (discussed below). Previous
immunocytochemical studies have localized IGF-I peptide along
most of the nephron of the adult rat kidney, with the most intense
and consistent staining pattern noted in cells (primarily principal
cells) of the collecting duct system (Table 1). Additional (although
less frequent) immunoreactive IGF-I are located in the glomeru-
lus, proximal tubules, thin ioops of Henle, thick ascending limbs
and the distal tubule (Table 1). The variability from published
data most likely represents technical differences known to influ-
ence the intensity of immunostaining, such as the fixative and
tissue processing [59, 66]. This is the first immunocytochemical
study of IGF-II in the adult rat kidney. The co-localization of
IGF-I and -II with the IGF-II/M6P receptors in the collecting duct
suggests that the principal cells may be a site of IGFs' degrada-
tion. The IGF-II/M6P receptor, which is identical to the mam-
mose-6-phosphate receptor, is likely to provide a degradative
pathway for extracellular IGF-II from the circulation via receptor-
mediated internalization [691. Previously, IGF-II mRNA has been
localized to the lower pole of the S-shaped renal vesicle and
stromal cells associated with developing vasa recta, while IGF-II/
M6P receptor mRNA is abundant in medullary rays and the
medulla throughout the period of nephrogenesis [381. These data
have led Chin et al [38] to suggest that IGF-II has a role in renal
vascularization and possibly a more general function in angiogen-
esis. This hypothesis is supported by the localization of low levels
of IGF-II mRNA in renal (our own observation) and non-renal
vessels [651 in adult kidney as well as in the developing rat kidney
[38].
In the mammalian system, six high affinity IGFBPs have been
identified in the circulation and extracellular fluid [70]. These
IGFBPs can modulate the biological activities of IGFs in a target
tissue by transporting IGFs in and out of the vascular compart-
ment, targeting IGFs to specific cell types and modulating the
interaction between IGFs and their receptors. Among four IG-
FBPs (IGFBP1, 2, 3 and 5) produced in the adult kidney [25, 49,
59, 70—72], IGFBP1 and -2 have been better characterized.
IGFBP1 mRNA has a similar cellular distribution to that of IGF-I
and IGFR-I in the thick ascending limbs of the outer medulla [36],
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whereas IGFBP2 mRNA is localized to the visceral epithelial cells
of the renal corpuscle and interstitial cells of the inner medulla.
Both immunoreactive IGFBP1 and -2 have been localized to cells
of the distal nephron, where they may participate in targeting and
modulating IGFs' action. Interestingly, IGF-II mRNA and immu-
noreactive IGFBP2 are both localized to the vasculature (Table
1). With higher affinity to IGFBP2, IGF-II may be released and
transported as an IGF-II-IGFBP2 complex to other sites for
IGF-II's action, such as the proximal tubular cells where IGF-II,
not IGF-I and insulin, appears to stimulate Na-H exchange
across the apical membrane [16]. On the other hand, acute and
chronic infusions of IGF-I to normal rats increased GFR,
SNGFR, and RPF and also decreased renal vascular resistance
[24, 27, 73]. However, the sites and mechanism of IGF-I's action
on the glomerulus is still unknown. The cellular action of IGFs on
mature renal epithelial cells has been studied primarily on cul-
tured proximal tubular cells [7I and mesangial cells [73], for
which IGF-I is a potent mitogen. IGF-I also stimulates glucone-
ogenesis in dog proximal tubular cells in suspension [18], and
increases Nat-dependent P1 transport in cultured proximal tubu-
lar cells [20, 211 and in basolateral and apical membranes of
isolated perfused rabbit proximal tubular cells [19]. Previous
studies employing 1251-IGF-I reported IGF-I binding sites
throughout the kidney [37, 75—78], with specific 1251-IGF-I binding
in glomeruli and proximal tubules (in particular the basolateral
membranes) [75—78] or the inner medulla [37]. Since the specific
'251-IGF-I binding sites on the proximal tubular and glomerular
cells are upstream to sites of renal IGF-I synthesis in the mTAL,
it is likely that proximal tubular and glomerular cells are subject to
regulation by circulating IGFs transported by IGFBPs.
The functional role of renal IGF-I produced in mTAL has not
been fully investigated. The mTAL is a structurally and function-
ally unique nephron segment. Cells in the mTAL are character-
ized by their high density of mitochondria and elaborate interdig-
itating basolateral cell processes. In addition, this segment can
produce epidermal growth factor (EGF), Tamm-Horsfall protein
(structurally homologous to EGF precursor), PGF2, and now,
IGF-I, IGFR-I, and IGFBP1 and -2. Functionally, this segment is
termed "the diluting segment" due to its high impermeability to
the osmotic flow of water and the active NaC1 transport by a
specific symport (1 Na, 1 K, 2 Cl) in the apical membrane driven
by the Na/K-ATPase in the basolateral membrane. With an
increasing work load, the mTAL undergoes selective hypertrophy
which is observed following either the chronic infusion of thyroid
hormone [79] or ADH to the Brattleboro rat [80, 81], water
restriction/dry food diet [82], salt load [83], or a high protein diet
[84]. Interestingly, feeding rats with a high protein diet over time
increased IGF-I, but decreased IGFBP1 mRNA levels in the
mTAL [85]. This increased local production and decreased bind-
ing activity may result in an increase in IGF-I bioactivity which
may be partially responsible for the selective hypertrophy of the
mTAL [84]. While our data also support IGF-I's trophic activity in
kidney hypertrophy [10, 11, 42—44], we cannot rule out a trophic
response for IGF-Il, in that they are both elevated at day 5 and
share the same receptor. At five days post-nephrectomy, while the
cellular distribution remained unchanged, both immunoreactive
IGF-I and -II levels (by RIA) in the remaining kidney were
elevated, which agrees with a previous observation [441. As IGF-II
level fell over the next 28 days, IGF-I level stayed elevated. Since
serum IGF-I and -II levels were unchanged, the increased renal
IGF-I is likely from local production in the kidney. In fact, IGF-I
mRNA levels were increased in the cortical, inner and outer
medulla, suggesting an active functional role of IGF-I in stimu-
lating hypertrophy of mTAL. Interestingly, chronic infusion (with
a Alzet osmotic pump) of IGF-I directly into the renal paren-
chyma induced cell growth in the mTAL and straight and cortical
distal tubules, with minimal changes in the proximal tubules and
medullary collecting ducts [86]. Therefore, IGF-I produced in the
mTAL may play a trophic role in conditions associated with
increasing work load such as high protein diet and unilateral
nephrectomy.
IGF-I and IGFR-I have been implicated in not only the
structural, but also functional recovery of the kidney following
acute tubular necrosis, diabetes mellitus and compensatory hyper-
trophy following nephron loss [recently reviewed in 671. The most
convincing evidence is from studies using a classical "high-
resistance" epithelium-toad urinary bladder, a functional model
of the principal cells of the collecting duct. The toad urinary
bladder cells and collecting duct cells of the cortex and outer
stripe of the outer medulla contain both Na and K conduc-
tances that favor Na absorption and K secretion, are rich in
Na47K-ATPase at the basolateral membranes, and possess V2
arginine vasopressin (AVP) receptors at the apical membranes.
Nanomolar concentrations of IGF-I stimulated Na transport in
the toad urinary bladder [22, 23], and this natriuretic effect of
IGF-I was evident within minutes and reached a maximum in two
to three hours without new protein synthesis [231. The IGF-I
response to increased vectorial Na transport was inhibited by
amiloride at a concentration known to specifically block the
conductive apical Na channel with little effect on the Na-H
antiporter. Therefore, data from the toad urinary bladder suggests
that IGF-I may increase vectorial Na transport in the distal
nephron by (1) increasing intracellular Na concentrations and
thereby providing an intracellular signal for augmented growth
[87], or (2) reflecting a mechanism by which the distal nephron
responds to the need of increased Na reabsorption that charac-
terizes the growing kidney and compensatory hypertrophy. It is
therefore conceivable that following nephrectomy newly synthe-
sized IGF-I in the mTAL has at least two potential actions: (1)
stimulating selective hypertrophy of mTAL, and (2) upon release,
IGF-I is transported downstream to stimulate Na transport in
collecting duct cells via the IGFR-I.
In conclusion, we have provided important evidence concern-
ing the renal sites of IGFs' synthesis and action by employing
immunocytochemistry and in situ hybridization on serial sections.
Renal IGFs are from two sources: local synthesis and extrarenal
circulation. IGF-I is locally produced in the medullary thick
ascending limb, an upstream location to its primary site of binding
along collecting duct. The evidence of extrarenal sources of IGF-I
is provided by immunoreactive IGF-I found in tubular cells
proximal to the site of IGF-I synthesis. The co-localization of
IGF-I, -II and IGF-II/M6P receptors in principal cells of the
collecting duct suggests that these cells are major sites of IGFs'
action and/or degradation. Finally, the increases in renal IGF-I
mRNA and peptide levels after nephrectomy support IGF-I's role
in structural and functional recovery in compensatory hypertro-
phy.
Reprint requests to Andrew P. Evan, Ph.D., Department of Anatomy,
Indiana Universily, School of Medicine, Indianapolis, Indiana 46202-5120,
USA.
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